Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?

GRACE Videos and Articles

Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.



craig's picture

Stage 4 ROS1+ [mucinous BAC] adenocarcinoma NSCLC since 2011
Xalkori (crizotinib) 5 yrs
Alimta (pemetrexed) + carboplatin (mere months)
TPX-0005 (repotrectinib) TBD (1+ years as of Fall 2018)


Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation